Pelthos Therapeutics Inc.(PTHS)Earnings, Financials & Key Ratios
PTHS•NYSE
Price updated Jun 19, 2026
AboutPelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.Show more
- Revenue$17M
- EBITDA-$30M-319.5%
- Net Income-$43M-444.5%
- EPS (Diluted)-23.04-70.2%
- Gross Margin62.65%
- EBITDA Margin-179.05%
- Operating Margin-193.09%
- Net Margin-257.93%
- ROE-239.55%
PTHS Key Insights
Pelthos Therapeutics Inc. (PTHS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PTHS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTHS Price & Volume
Pelthos Therapeutics Inc. (PTHS) stock price & volume — 10-year historical chart
Loading chart...
PTHS Growth Metrics
Pelthos Therapeutics Inc. (PTHS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-600.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-228.15%
Return on Capital
10 Years-63.78%
5 Years-63.78%
3 Years-63.78%
Last Year-63.78%
PTHS Peer Comparison
Pelthos Therapeutics Inc. (PTHS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 |
Compare PTHS vs Peers
Pelthos Therapeutics Inc. (PTHS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTHS Income Statement
Pelthos Therapeutics Inc. (PTHS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 16.8M | 27.7M |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 6.27M | 9.45M |
COGS % of Revenue | - | - | - | 37.35% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 10.52M▲ 0% | 18.25M▲ 0% |
Gross Margin % | - | - | - | 62.65% | 65.9% |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 2.32M | 6.86M | 7.57M | 42.95M | 61.94M |
OpEx % of Revenue | - | - | - | 255.74% | - |
Selling, General & Admin | 1.93M | 4.28M | 6.39M | 41.72M | 60.72M |
SG&A % of Revenue | - | - | - | 248.43% | - |
Research & Development | 391.73K | 2.58M | 1.18M | 1.23M | 1.22M |
R&D % of Revenue | - | - | - | 7.31% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
Operating Income | -2.32M▲ 0% | -6.86M▼ 196.0% | -7.57M▼ 10.3% | -32.43M▼ 328.3% | -43.68M▲ 0% |
Operating Margin % | - | - | - | -193.09% | -157.7% |
Operating Income Growth % | - | -196.02% | -10.33% | -328.32% | - |
EBITDA | -2.32M | -6.86M | -7.17M | -30.07M | -39.75M |
EBITDA Margin % | - | - | - | -179.05% | -143.51% |
EBITDA Growth % | - | -196.02% | -4.47% | -319.46% | -462.38% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 2.36M | 3.93M |
EBIT | -2.32M | -6.86M | -7.17M | -32.43M | -43.68M |
Net Interest Income | -140.43K | -518.51K | -786.39K | -3.01M | -5.23M |
Interest Income | 0 | 0 | 0 | 5K | 5K |
Interest Expense | 140.43K | 518.51K | 786.39K | 3.01M | 5.23M |
Other Income/Expense | -140.43K | -518.51K | -383.89K | -18.28M | -15.29M |
Pretax Income | -2.46M▲ 0% | -7.38M▼ 200.2% | -7.96M▼ 7.8% | -50.71M▼ 537.4% | -58.98M▲ 0% |
Pretax Margin % | - | - | - | -301.91% | -212.9% |
Income Tax | 0 | 0 | 0 | -7.39M | -7.39M |
Effective Tax Rate % | 0% | 0% | 0% | 14.57% | 12.53% |
Net Income | -2.46M▲ 0% | -7.38M▼ 200.2% | -7.96M▼ 7.8% | -43.32M▼ 444.5% | -51.59M▲ 0% |
Net Margin % | - | - | - | -257.93% | -186.23% |
Net Income Growth % | - | -200.2% | -7.78% | -444.53% | -600.88% |
Net Income (Continuing) | -2.46M | -7.38M | -7.96M | -43.32M | -51.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.26▲ 0% | -12.80▼ 200.5% | -13.54▼ 5.8% | -23.04▼ 70.2% | -15.58▲ 0% |
EPS Growth % | - | -200.47% | -5.78% | -70.16% | -228.15% |
EPS (Basic) | -4.26 | -12.80 | -13.54 | -23.04 | - |
Diluted Shares Outstanding | 576.75K | 576.75K | 587.62K | 1.88M | 3.31M |
Basic Shares Outstanding | 576.75K | 576.75K | 587.62K | 1.88M | 3.31M |
Dividend Payout Ratio | - | - | - | - | - |
PTHS Balance Sheet
Pelthos Therapeutics Inc. (PTHS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 55.07K | 96.39K | 1.37M | 52.7M | 69.09M |
Cash & Short-Term Investments | 55.07K | 96.39K | 513.44K | 18.02M | 32.23M |
Cash Only | 55.07K | 96.39K | 513.44K | 18.02M | 32.23M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 40.4K | 8.86M | 11.7M |
Days Sales Outstanding | - | - | - | 192.51 | 94.17 |
Inventory | 0 | 0 | 0 | 23.57M | 23.42M |
Days Inventory Outstanding | - | - | - | 1.37K | 686.72 |
Other Current Assets | 0 | 0 | 750K | 419K | 545K |
Total Non-Current Assets | 0 | 0 | 0 | 77.7M | 76.29M |
Property, Plant & Equipment | 0 | 0 | 0 | 12.84M | 12.46M |
Fixed Asset Turnover | - | - | - | 1.31x | 2.85x |
Goodwill | 0 | 0 | 0 | 24.68M | 24.68M |
Intangible Assets | 0 | 0 | 0 | 39.47M | 38.44M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 711K | 711K |
Total Assets | 55.07K▲ 0% | 96.39K▲ 75.0% | 1.37M▲ 1320.4% | 130.4M▲ 9424.0% | 145.38M▲ 0% |
Asset Turnover | - | - | - | 0.13x | 0.27x |
Asset Growth % | - | 75.02% | 1320.41% | 9423.99% | 31018.92% |
Total Current Liabilities | 3.76M | 6.54M | 4.08M | 25.99M | 25M |
Accounts Payable | 2.99M | 4.62M | 1.9M | 2.99M | 6.15M |
Days Payables Outstanding | - | - | - | 173.74 | 191.15 |
Short-Term Debt | 540.43K | 1.27M | 2.19M | 635K | 640K |
Deferred Revenue (Current) | 0 | 0 | 0 | 966K | 2.96M |
Other Current Liabilities | 221.88K | 645.95K | 0 | 21.41M | 15.3M |
Current Ratio | 0.01x | 0.01x | 0.34x | 2.03x | 2.76x |
Quick Ratio | 0.01x | 0.01x | 0.34x | 1.12x | 1.83x |
Cash Conversion Cycle | - | - | - | 1.39K | 589.74 |
Total Non-Current Liabilities | 0 | 0 | 0 | 65.52M | 85.27M |
Long-Term Debt | 0 | 0 | 0 | 31.44M | 49.64M |
Capital Lease Obligations | 0 | 0 | 0 | 2.75M | 8.25M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 12.87M |
Other Non-Current Liabilities | 0 | 0 | 0 | 30.05M | 31.95M |
Total Liabilities | 3.76M | 6.54M | 4.08M | 91.52M | 110.28M |
Total Debt | 540.43K | 1.27M | 2.19M | 34.83M | 52.93M |
Net Debt | 485.36K | 1.17M | 1.67M | 16.8M | 20.7M |
Debt / Equity | - | - | - | 0.90x | 1.51x |
Debt / EBITDA | - | - | - | - | -1.33x |
Net Debt / EBITDA | - | - | - | - | -0.52x |
Interest Coverage | -16.51x | -13.23x | -9.12x | -10.77x | -8.35x |
Total Equity | -3.71M▲ 0% | -6.44M▼ 73.9% | -2.71M▲ 57.9% | 38.88M▲ 1532.6% | 35.1M▲ 0% |
Equity Growth % | - | -73.87% | 57.89% | 1532.58% | 3191.85% |
Book Value per Share | -6.43 | -11.17 | -4.62 | 20.68 | 10.60 |
Total Shareholders' Equity | -3.71M | -6.44M | -2.71M | 38.88M | 35.1M |
Common Stock | 111 | 391 | 613 | 0 | 0 |
Retained Earnings | -6.14M | -13.52M | -21.47M | -64.79M | -75.03M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 3.19M |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
PTHS Cash Flow Statement
Pelthos Therapeutics Inc. (PTHS) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -1.57M | -981.03K | -5.79M | -22.59M | -35.08M |
Operating CF Margin % | - | - | - | -134.5% | - |
Operating CF Growth % | - | 37.4% | -490.45% | -289.99% | -11201% |
Net Income | -2.46M | -7.38M | -7.96M | -43.32M | -51.59M |
Depreciation & Amortization | 0 | 0 | 0 | 2.36M | 3.93M |
Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 | 413.49K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M | 21.42M |
Working Capital Changes | 640.86K | 2.05M | 34.63K | -6.07M | -9.26M |
Change in Receivables | 0 | 0 | -45.79K | -8.81M | -11.65M |
Change in Inventory | 0 | 0 | 0 | 1.78M | 549K |
Change in Payables | 413.6K | 1.63M | 1.18M | 1.36M | 3.81M |
Cash from Investing | 0 | 0 | 0 | -5.24M | -5.43M |
Capital Expenditures | 0 | 0 | 0 | -99K | -293K |
CapEx % of Revenue | - | - | - | 0.59% | 1.06% |
Acquisitions | 0 | 0 | 0 | -5.14M | -5.14M |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.62M | 1.02M | 6.21M | 45.34M | 72.61M |
Debt Issued (Net) | 400K | 766.94K | 321.43K | 17.75M | 45.02M |
Equity Issued (Net) | 0 | 255.41K | 5.89M | 27.59M | 27.59M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -166.51K | 0 | 0 |
Other Financing | 1.22M | 0 | 0 | 0 | 0 |
Net Change in Cash | 55.07K▲ 0% | 41.32K▼ 25.0% | 417.05K▲ 909.4% | 17.51M▲ 4098.4% | 32.02M▲ 0% |
Free Cash Flow | -1.57M▲ 0% | -981.03K▲ 37.4% | -5.79M▼ 490.4% | -22.69M▼ 291.7% | -35.38M▲ 0% |
FCF Margin % | - | - | - | -135.09% | -127.71% |
FCF Growth % | - | 37.4% | -490.45% | -291.7% | -698.09% |
FCF per Share | -2.72 | -1.70 | -9.86 | -12.07 | -10.68 |
FCF Conversion (FCF/Net Income) | 0.64x | 0.13x | 0.73x | 0.52x | 0.69x |
Interest Paid | 0 | 0 | 0 | 0 | 7.5K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
PTHS Key Ratios
Pelthos Therapeutics Inc. (PTHS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | - | - | -239.55% | -164.11% |
Return on Invested Capital (ROIC) | - | - | -89.02% | -84.7% |
Gross Margin | - | - | 62.65% | 65.9% |
Net Margin | - | - | -257.93% | -186.23% |
Debt / Equity | - | - | 0.90x | 1.51x |
Interest Coverage | -13.23x | -9.12x | -10.77x | -8.35x |
FCF Conversion | 0.13x | 0.73x | 0.52x | 0.69x |
Related:PTHS Dividend History·PTHS Revenue History·PTHS Price History·PTHS P/E History·PTHS Financial Ratios·PTHS Institutional Holders
PTHS Frequently Asked Questions
Pelthos Therapeutics Inc. (PTHS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pelthos Therapeutics Inc. (PTHS) reported $27.7M in revenue for fiscal year 2025.
Pelthos Therapeutics Inc. (PTHS) grew revenue by 0.0% over the past year. Growth has been modest.
Pelthos Therapeutics Inc. (PTHS) reported a net loss of $51.6M for fiscal year 2025.
Dividend & Returns
Pelthos Therapeutics Inc. (PTHS) has a return on equity (ROE) of -239.6%. Negative ROE indicates the company is unprofitable.
Pelthos Therapeutics Inc. (PTHS) had negative free cash flow of $35.4M in fiscal year 2025, likely due to heavy capital investments.